Scientific Reports

Table 2 Distribution of dominant and index tumor attending to the two software and their comparison with histopathologic distribution.

From: Analytical performance validation of aPROMISE platform for prostate tumor burden, index and dominant tumor assessment with 18F-DCFPyL PET/CT. A pilot study

A
		DT Lobe MOLab			Total
		Right	Left		Total
DT lobe aPROMISE	Right	28	3		31
DT lobe aPROMISE	Left	4	19		23
Total		32	22		54

B
		IT Lobe MOLab			Total
		Right	Left		Total
IT lobe aPROMISE	Right	28	4		32
IT lobe aPROMISE	Left	1	21		22
Total		29	25		54

C
		Histopathologic DT
		Right	Left	Both
DT lobe aPROMISE	Right	23	3	5	31
DT lobe aPROMISE	Left	2	17	4	23
Total		25	20	9	54

D
		Histopathologic IT			Total
		Right	Left	Both	Total
IT lobe aPROMISE	Right	23	6	3	32
IT lobe aPROMISE	Left	4	17	1	22
Total		27	23	4	54

E
		Histopathologic DT			Total
		Right	Left	Both	Total
DT lobe MOLab	Right	25	4	3	32
DT lobe MOLab	Left	0	16	6	22
Total		25	20	9	54

F
		Histopathologic IT			Total
		Right	Left	Both	Total
IT lobe MOLab	Right	22	6	1	29
IT lobe MOLab	Left	5	17	3	25
Total		27	23	4	54

The kappa values of the different concordances were: A: K = 0.733; B: K = 0.812; C: K = 0.550; D: K = 0.511; E: K = 0.581 and F: K = 0.480 with p < 0.001 in all the cases.

Back to article page

Search

Advanced search

Quick links